13 Jan 2026 Continue to Offer RSV Immunization
RSV activity is elevated in many areas of the country, including Pennsylvania and Philadelphia. RSV (respiratory syncytial virus) immunization remains the most effective protection against RSV illness. A recent study showed that nirsevimab was 81% effective against RSV-associated hospitalization among infants younger than 6 months.
Refer to these previous messages regarding availability and ordering of nirsevimab and clesrovimab from the Vaccines for Children (VFC) program:
RSV immunizations are available to order through the VFC program.
View available RSV immunization products below:
